What is the share price of Mercury Laboratories Ltd (MERCURYLAB) today?
The share price of MERCURYLAB as on 24th July 2026 is ₹835. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Mercury Laboratories Ltd (MERCURYLAB) share?
The past returns of Mercury Laboratories Ltd (MERCURYLAB) share are- Past 1 week: -5.86%
- Past 1 month: -1.52%
- Past 3 months: 17.08%
- Past 6 months: 4.40%
- Past 1 year: -4.02%
- Past 3 years: 6.72%
- Past 5 years: 11.95%
What are the peers or stocks similar to Mercury Laboratories Ltd (MERCURYLAB)?
The peers or stocks similar to Mercury Laboratories Ltd (MERCURYLAB) include:What is the dividend yield % of Mercury Laboratories Ltd (MERCURYLAB) share?
The current dividend yield of Mercury Laboratories Ltd (MERCURYLAB) is 0.42.What is the market cap of Mercury Laboratories Ltd (MERCURYLAB) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Mercury Laboratories Ltd (MERCURYLAB) is ₹100.20 Cr as of 24th July 2026.What is the 52 week high and low of Mercury Laboratories Ltd (MERCURYLAB) share?
The 52-week high of Mercury Laboratories Ltd (MERCURYLAB) is ₹976 and the 52-week low is ₹620.55.What is the PE and PB ratio of Mercury Laboratories Ltd (MERCURYLAB) stock?
The P/E (price-to-earnings) ratio of Mercury Laboratories Ltd (MERCURYLAB) is 20.70. The P/B (price-to-book) ratio is 1.87.Which sector does Mercury Laboratories Ltd (MERCURYLAB) belong to?
Mercury Laboratories Ltd (MERCURYLAB) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Mercury Laboratories Ltd (MERCURYLAB) shares?
You can directly buy Mercury Laboratories Ltd (MERCURYLAB) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Mercury Laboratories Ltd
MERCURYLAB Share Price
BSE₹835.003.47% (+28.00)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
MERCURYLAB Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
MERCURYLAB Performance & Key Metrics
MERCURYLAB Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 24.03 | 1.87 | 0.42% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 44.74 | 5.90 | 0.53% |
MERCURYLAB Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
MERCURYLAB Company Profile
Mercury Laboratories Limited is a pharmaceutical company engaged in the manufacturing of pharmaceuticals, medicinal drugs and formulations.
SUNPHARMA
PE Ratio
40.57
40.57
1Y Return
14.72%
14.72%
Buy Reco %
93.75
93.75
TORNTPHARM
PE Ratio
87.23
87.23
1Y Return
40.96%
40.96%
Buy Reco %
78.57
78.57
CIPLA
PE Ratio
29.38
29.38
1Y Return
5.20%
5.20%
Buy Reco %
66.67
66.67
ZYDUSLIFE
PE Ratio
21.94
21.94
1Y Return
14.15%
14.15%
Buy Reco %
55.17
55.17
LUPIN
PE Ratio
20.32
20.32
1Y Return
22.10%
22.10%
Buy Reco %
55.56
55.56
MERCURYLAB Forecast
MERCURYLAB Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
MERCURYLAB
MERCURYLAB
Income
Balance Sheet
Cash Flow
Quarterly Normal View
MERCURYLAB Income Statement
MERCURYLAB Income Statement
Quarterly Normal View
| Quarter | mar 2024 | jun 2024 | sep 2024 | dec 2024 | mar 2025 | jun 2025 | sep 2025 | dec 2025 | mar 2026 | jun 2026 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 17.78 | 16.83 | 18.40 | 20.10 | 20.84 | 18.32 | 19.80 | 18.66 | 21.11 | 16.02 | ||||||||||
Operating & Other expenses | 14.72 | 15.07 | 16.88 | 17.60 | 18.54 | 15.78 | 16.88 | 16.23 | 18.40 | 14.77 | ||||||||||
EBITDA | 3.06 | 1.76 | 1.52 | 2.50 | 2.30 | 2.54 | 2.92 | 2.43 | 2.71 | 1.25 | ||||||||||
| Depreciation/Amortization | 0.72 | 0.70 | 0.71 | 0.74 | 0.73 | 0.84 | 0.86 | 0.87 | 0.84 | 0.73 | ||||||||||
| PBIT | 2.34 | 1.06 | 0.81 | 1.76 | 1.57 | 1.70 | 2.06 | 1.56 | 1.87 | 0.52 | ||||||||||
| Interest & Other Items | 0.10 | 0.14 | 0.15 | 0.13 | 0.13 | 0.15 | 0.13 | 0.14 | 0.13 | 0.12 | ||||||||||
| PBT | 2.24 | 0.92 | 0.66 | 1.63 | 1.44 | 1.55 | 1.93 | 1.42 | 1.74 | 0.40 | ||||||||||
| Taxes & Other Items | 0.34 | 0.58 | 0.15 | 0.45 | 0.34 | 0.58 | 0.28 | 0.44 | 0.51 | 0.09 | ||||||||||
| Net Income | 1.90 | 0.34 | 0.51 | 1.18 | 1.10 | 0.97 | 1.65 | 0.98 | 1.23 | 0.31 | ||||||||||
| EPS | 15.92 | 2.85 | 4.17 | 9.94 | 9.25 | 8.06 | 13.69 | 8.31 | 10.21 | 2.48 |
MERCURYLAB Company Updates
MERCURYLAB Stock Peers
MERCURYLAB Past Performance & Peer Comparison
MERCURYLAB Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Mercury Laboratories Ltd | 20.70 | 1.87 | 0.42% |
| Sun Pharmaceutical Industries Ltd | 40.57 | 5.55 | 0.82% |
| Torrent Pharmaceuticals Ltd | 87.23 | 10.73 | 0.68% |
| Cipla Ltd | 29.38 | 3.30 | 0.92% |
MERCURYLAB Stock Price Comparison
Compare MERCURYLAB with any stock or ETFCompare MERCURYLAB with any stock or ETF
MERCURYLAB
MERCURYLAB Holdings
MERCURYLAB Shareholdings
MERCURYLAB Promoter Holdings Trend
MERCURYLAB Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
MERCURYLAB Institutional Holdings Trend
MERCURYLAB Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
MERCURYLAB Shareholding Pattern
MERCURYLAB Shareholding Pattern
MERCURYLAB Shareholding History
MERCURYLAB Shareholding History
Foreign Institutions
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing MERCURYLAB stock
smallcases containing MERCURYLAB stock
Looks like this stock is not in any smallcase yet.
MERCURYLAB Events
MERCURYLAB Events
MERCURYLAB Dividend Trend
No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year
MERCURYLAB has increased or maintained dividend levels over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.42%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹4.19 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
MERCURYLAB Dividend Trend
No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year
MERCURYLAB has increased or maintained dividend levels over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.42%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹4.19 every year
MERCURYLAB Upcoming Dividends
MERCURYLAB Upcoming Dividends
No upcoming dividends are available
MERCURYLAB Past Dividends
MERCURYLAB Past Dividends
Cash Dividend
Ex DateEx DateAug 6, 2025
Final
Final | Div/Share: ₹3.50
Dividend/Share
₹3.50
Ex DateEx Date
Aug 6, 2025
Cash Dividend
Ex DateEx DateSep 20, 2024
Final
Final | Div/Share: ₹3.50
Dividend/Share
₹3.50
Ex DateEx Date
Sep 20, 2024
Cash Dividend
Ex DateEx DateSep 20, 2023
Final
Final | Div/Share: ₹3.50
Dividend/Share
₹3.50
Ex DateEx Date
Sep 20, 2023
Cash Dividend
Ex DateEx DateSep 19, 2022
Final
Final | Div/Share: ₹3.50
Dividend/Share
₹3.50
Ex DateEx Date
Sep 19, 2022
Cash Dividend
Ex DateEx DateSep 20, 2021
Final
Final | Div/Share: ₹2.00
Dividend/Share
₹2.00
Ex DateEx Date
Sep 20, 2021
MERCURYLAB Stock News & Opinions
MERCURYLAB Stock News & Opinions
Articles & Videos
Earnings
Earnings
Mercury Laboratories standalone net profit declines 69.07% in the June 2026 quarterNet profit of Mercury Laboratories declined 69.07% to Rs 0.30 crore in the quarter ended June 2026 as against Rs 0.97 crore during the previous quarter ended June 2025. Sales declined 12.02% to Rs 15.96 crore in the quarter ended June 2026 as against Rs 18.14 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales15.9618.14 -12 OPM %7.4613.01 - PBDT1.122.39 -53 PBT0.391.55 -75 NP0.300.97 -69 Powered by Capital Market - Live
1 day agoCapital Market - Live
Corporate
Corporate
Mercury Laboratories to convene board meetingMercury Laboratories will hold a meeting of the Board of Directors of the Company on 25 July 2026.
1 week agoCapital Market - Live
Corporate
Corporate
Mercury Laboratories AGM scheduledMercury Laboratories announced that the Annual General Meeting(AGM) of the company will be held on 28 September 2026.
1 month agoCapital Market - Live
Corporate
Corporate
Board of Mercury Laboratories recommends final dividendMercury Laboratories announced that the Board of Directors of the Company at its meeting held on 29 May 2026, inter alia, have recommended the final dividend of Rs 3.5 per equity Share (i.e. 35%) , subject to the approval of the shareholders.
1 month agoCapital Market - Live
Corporate
Corporate
Mercury Laboratories to discuss resultsMercury Laboratories will hold a meeting of the Board of Directors of the Company on 29 May 2026.
2 months agoCapital Market - Live
Earnings
Earnings
Mercury Laboratories standalone net profit declines 15.97% in the December 2025 quarterNet profit of Mercury Laboratories declined 15.97% to Rs 1.00 crore in the quarter ended December 2025 as against Rs 1.19 crore during the previous quarter ended December 2024. Sales declined 6.23% to Rs 18.35 crore in the quarter ended December 2025 as against Rs 19.57 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales18.3519.57 -6 OPM %13.7910.12 - PBDT2.702.38 13 PBT1.831.64 12 NP1.001.19 -16 Powered by Capital Market - Live
5 months agoCapital Market - Live
Corporate
Corporate
Mercury Laboratories to table resultsMercury Laboratories will hold a meeting of the Board of Directors of the Company on 11 February 2026.Powered by Capital Market - Live
5 months agoCapital Market - Live
Earnings
Earnings
Mercury Laboratories standalone net profit rises 228.00% in the September 2025 quarterNet profit of Mercury Laboratories rose 228.00% to Rs 1.64 crore in the quarter ended September 2025 as against Rs 0.50 crore during the previous quarter ended September 2024. Sales rose 4.51% to Rs 19.01 crore in the quarter ended September 2025 as against Rs 18.19 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales19.0118.19 5 OPM %11.157.15 - PBDT2.781.36 104 PBT1.920.65 195 NP1.640.50 228 Powered by Capital Market - Live
8 months agoCapital Market - Live
Corporate
Corporate
Mercury Laboratories to table resultsMercury Laboratories will hold a meeting of the Board of Directors of the Company on 11 November 2025.Powered by Capital Market - Live
8 months agoCapital Market - Live
Earnings
Earnings
Mercury Laboratories standalone net profit rises 185.29% in the June 2025 quarterNet profit of Mercury Laboratories rose 185.29% to Rs 0.97 crore in the quarter ended June 2025 as against Rs 0.34 crore during the previous quarter ended June 2024. Sales rose 8.75% to Rs 18.14 crore in the quarter ended June 2025 as against Rs 16.68 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales18.1416.68 9 OPM %13.019.65 - PBDT2.391.62 48 PBT1.550.92 68 NP0.970.34 185 Powered by Capital Market - Live
11 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 2.31%, vs industry avg of 12.48%
Over the last 5 years, market share stayed at 0.02%
Over the last 5 years, net income has grown at a yearly rate of -1.95%, vs industry avg of 10.55%